
Evonik is investing more than CAD$150 million (€93 million/around £68 million) in a new pharmaceutical manufacturing facility in Canada as it prepares for growing demand for lipid nanoparticle-based medicines.
The new GMP facility in Vancouver will more than triple the company’s manufacturing capacity for advanced pharmaceutical products, supporting the development of vaccines, therapeutics and other medicines using lipid-based drug delivery technologies.
Production is scheduled to begin at the end of 2029, with the Canadian federal government’s Strategic Response Fund providing up to CAD$68 million (€42 million) towards the project.
The investment reflects growing pharmaceutical interest in lipid nanoparticles (LNPs), which are used to encapsulate and deliver active ingredients including nucleic acid-based drugs such as mRNA.
“Lipid-based drug delivery technologies are already enabling the next generation of medicines. With the support of the Canadian federal government, this investment builds on our long-standing expertise in the field, enabling the development and commercialization of more life-changing therapies,” said Lauren Kjeldsen, member of Evonik’s Executive Board and COO for the Custom Solutions segment at Evonik.
Manufacturing Capacity to More Than Triple
The new facility will operate according to Good Manufacturing Practice standards and significantly expand Evonik’s existing Vancouver operations.
Alongside more than tripling manufacturing capacity, the development will increase the company’s quality control and microbiological testing capabilities.
Evonik says this should improve efficiency and help support the timely release of pharmaceutical products for use in clinical studies.
The site will work with pharmaceutical and biotechnology companies developing lipid-based medicines, providing capabilities intended to help products progress from development towards clinical manufacturing and ultimately commercial-scale production.
“The Vancouver region is a vibrant hub for life sciences innovation, and Evonik’s Health Care business is proud to be growing within and with this ecosystem. This investment strengthens both our regional presence and our global network for lipid-based drug delivery,” said Guido Skudlarek, head of Evonik’s Health Care business line.
LNP Technology Growing Beyond Covid Vaccines
Lipid nanoparticles gained widespread attention through their role in delivering mRNA in Covid-19 vaccines, but the technology has much broader potential.
Lipids can encapsulate nucleic acid-based medicines and other pharmaceutical payloads, helping transport them through the body and into their intended target cells.
As research into mRNA and other nucleic acid therapeutics accelerates, demand for the specialist development and manufacturing capabilities required to produce LNP-based medicines is also expected to increase.
The LNP market alone is projected to reach US$2.7 billion by 2034.
Evonik Vancouver Laboratories has worked in lipid-based drug delivery since the 1990s. Formerly known as Transferra Nanosciences and Northern Lipids, it now provides contract development and manufacturing organisation (CDMO) services covering advanced LNP and liposomal delivery systems.
Its work ranges from formulation research and GMP clinical trial manufacturing to scaling processes for commercial production.
Canada Backs Expansion of Life Sciences Manufacturing
The Canadian government says the investment will also strengthen British Columbia’s growing biotechnology sector.
More than 2,000 life sciences businesses are based in the province, employing almost 20,000 people, with many concentrated around Greater Vancouver.
“Evonik’s expansion in Vancouver underscores Canada’s leadership in life sciences and innovation. This investment will drive advances in lipid-based drug delivery, create highly skilled jobs, and bolster British Columbia’s growing biotech ecosystem. The Government of Canada is proud to support Evonik’s goals, which will help position Canada at the forefront of next-generation vaccines and medicines,” said the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions.
Building a Global LNP Manufacturing Network
Vancouver forms one part of Evonik’s wider international network supporting the development and manufacture of lipids and lipid nanoparticles.
LNP formulations are developed in Vancouver, with processes for advanced clinical trials and commercial manufacturing transferred to the company’s operation in Birmingham, Alabama.
Additional lipid and adjuvant supplies come from Dossenheim and Hanau in Germany, while research and development capabilities are based at the Cambridge Innovation Satellite in Greater Boston.
Evonik is also constructing a global-scale lipid production facility at its Tippecanoe Laboratories site in Lafayette, Indiana.
The company says bringing together expertise in lipid chemistry, formulation, sterile manufacturing, process engineering and regulation across the network will allow it to support pharmaceutical developers from early-stage research through GMP manufacturing and eventual commercial supply.
The Vancouver expansion is expected to further increase that capacity at a time when LNP technology is moving beyond its high-profile use in vaccines and becoming an increasingly important delivery platform for a new generation of advanced medicines.